SIGA Technologies Inc (SIGA)
NASDAQ:SIGA
Top Page
SIGA Technologies
(NASDAQ:SIGA)
Select Model
Select Model
Rating:67Neutral
Price Target:
$5.00
▼(-26.14% Downside)
Action:ReiteratedDate:04/10/26
The score is primarily supported by strong balance sheet strength (minimal leverage) and generally healthy cash generation, but it is tempered by significant recent volatility in revenue/profitability and weak technical trend signals (below key moving averages with negative MACD). Valuation is moderate and the special dividend is a positive secondary factor.
Positive Factors
Conservative balance sheet
Near-zero leverage provides durable financial flexibility: it lowers solvency risk, supports investments in manufacturing and readiness, and lets management bridge lumpy procurement cycles without needing external financing, preserving strategic optionality over months.
Negative Factors
Revenue volatility
Large, abrupt revenue swings reflect dependency on episodic procurement and outbreak-driven demand. Such volatility hampers multi-quarter planning, makes operating leverage unpredictable, and raises execution risk for capacity and R&D investments over the next several months.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Near-zero leverage provides durable financial flexibility: it lowers solvency risk, supports investments in manufacturing and readiness, and lets management bridge lumpy procurement cycles without needing external financing, preserving strategic optionality over months.
Read all positive factors
SIGA Technologies (SIGA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$312.37M
Dividend YieldN/A
Average Volume (3M)461.52K
Price to Earnings (P/E)18.8
Beta (1Y)1.28
Revenue Growth-0.85%
EPS Growth-13.50%
CountryUS
Employees46
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.08
Shares Outstanding71,644,400
10 Day Avg. Volume376,632
30 Day Avg. Volume461,516
Financial Highlights & Ratios
PEG Ratio-0.31
Price to Book (P/B)2.20
Price to Sales (P/S)4.62
P/FCF Ratio8.98
Enterprise Value/Market Cap0.51
Enterprise Value/Revenue1.67
Enterprise Value/Gross Profit2.44
Enterprise Value/Ebitda5.73
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.7
Revenue Forecast (FY)$226.55M
SIGA Technologies Business Overview & Revenue Model
Company Description
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallp...
How the Company Makes Money
SIGA makes money primarily by selling its antiviral TPOXX (tecovirimat) under procurement and supply arrangements, historically driven largely by government demand for national stockpiles and outbreak response. Key revenue streams include: (1) Pro...
SIGA Technologies Earnings Call Summary
Earnings Call Date:Nov 06, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Apr 30, 2026
Earnings Call Sentiment Neutral
The earnings call reflected a strong financial position and positive growth in product sales, driven by continued engagement with government contracts and international sales potential. However, challenges such as potential delays due to the government shutdown, questions from the EMA, and quarterly revenue fluctuations were also noted.Positive Updates
Strong Financial Position
SIGA maintains a robust cash balance of $172 million with no debt, providing flexibility and enabling the company to pursue opportunities and manage risks effectively.
Negative Updates
Impact of Government Shutdown
Potential delays in CDC analysis of samples for the PEP program due to the government shutdown, impacting timelines.
Read all updates
Q3-2025 Updates
Positive
Negative
Strong Financial Position
SIGA maintains a robust cash balance of $172 million with no debt, providing flexibility and enabling the company to pursue opportunities and manage risks effectively.
Read all positive updates
Company Guidance
During the third quarter of 2025, SIGA Technologies reported product revenues of approximately $86 million for the nine months ending September 30, 2025, with $53 million from oral TPOXX and $26 million from IV TPOXX sales under the 19C BARDA contract, and $6 million from international oral TPOXX sales. The company highlighted a relatively quiet third quarter following a strong second quarter, which included $79 million in product revenues. Pre-tax operating income for the first nine months was about $33 million, while the third quarter saw a pre-tax operating loss of approximately $10 million. The net income for the nine months was around $29 million, equating to a fully diluted income per share of $0.40, whereas the net loss for the third quarter was about $6 million, or $0.09 per share. SIGA ended the quarter with a cash balance of $172 million and no debt, maintaining a strong financial position. The company also noted $26 million in outstanding orders from the U.S. government, expected for delivery in 2026, and ongoing strategic discussions with government and international stakeholders concerning future TPOXX procurement and development.SIGA Technologies Financial Statement Overview
Summary
Income Statement
66
Positive
Balance Sheet
82
Very Positive
Cash Flow
74
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 94.60M | 138.72M | 139.92M | 110.78M | 133.67M |
| Gross Profit | 64.87M | 107.43M | 122.09M | 100.34M | 117.07M |
| EBITDA | 24.26M | 70.52M | 84.16M | 43.22M | 89.62M |
| Net Income | 23.30M | 59.21M | 68.07M | 33.90M | 69.45M |
Balance Sheet | |||||
| Total Assets | 219.47M | 244.34M | 254.35M | 195.04M | 214.73M |
| Cash, Cash Equivalents and Short-Term Investments | 154.97M | 155.40M | 150.15M | 98.79M | 103.14M |
| Total Debt | 595.17K | 546.82K | 564.01K | 528.17K | 466.83K |
| Total Liabilities | 20.65M | 28.53M | 57.49M | 24.88M | 40.41M |
| Stockholders Equity | 198.82M | 215.80M | 196.86M | 170.16M | 174.31M |
Cash Flow | |||||
| Free Cash Flow | 48.72M | 48.72M | 94.78M | 41.61M | 11.44M |
| Operating Cash Flow | 48.76M | 48.76M | 94.80M | 41.61M | 11.49M |
| Investing Cash Flow | -42.45K | -42.45K | -21.69K | 0.00 | -50.62K |
| Financing Cash Flow | -43.46M | -43.46M | -43.42M | -45.96M | -26.20M |
SIGA Technologies Technical Analysis
Negative
6.77
Price Trends
5.28
Negative
5.43
Negative
6.24
Negative
Market Momentum
-0.20
Negative
36.48
Neutral
7.62
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SIGA, the sentiment is Negative. The current price of 6.77 is above the 20-day moving average (MA) of 4.55, above the 50-day MA of 5.28, and above the 200-day MA of 6.24, indicating a bearish trend. The MACD of -0.20 indicates Negative momentum. The RSI at 36.48 is Neutral, neither overbought nor oversold. The STOCH value of 7.62 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SIGA.
SIGA Technologies Risk Analysis
SIGA Technologies disclosed 37 risk factors in its most recent earnings report. SIGA Technologies reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
SIGA Technologies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $312.37M | 18.78 | 11.26% | ― | -0.85% | -13.50% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $411.09M | 12.57 | 9.59% | ― | -29.91% | ― | |
49 Neutral | $557.28M | -33.91 | 5.62% | ― | 2.83% | 13.61% | |
49 Neutral | $306.16M | 17.73 | 9.56% | ― | 2.24% | -67.56% | |
48 Neutral | $497.94M | -9.40 | 195.65% | ― | -26.32% | -56.54% |
* Healthcare Sector Average
SIGA
SIGA Technologies
4.36
-0.41
-8.60%
EBS
Emergent Biosolutions
7.96
3.57
81.32%
ESPR
Esperion
2.17
1.15
112.75%
ORGO
Organogenesis Holdings
2.38
-1.88
-44.13%
AQST
Aquestive Therapeutics
4.08
1.61
65.18%
SIGA Technologies Corporate Events
Dividends
SIGA Technologies Declares Special One-Time Cash Dividend
Positive
Mar 26, 2026
On March 26, 2026, SIGA Technologies, Inc. declared a special, one-time cash dividend of $0.60 per share of common stock, marking a return of capital to shareholders. The dividend will be paid on April 23, 2026 to investors of record as of April 7...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.